Effects of Darbepoetin Alfa Administered Every Two Weeks on Hemoglobin and Quality of Life of Patients Receiving Chemotherapy

Abels, R. (1993). Erythropoietin for anaemia in cancer patients. European Journal of Cancer, 29A(Suppl. 2), S2-S8.

Amgen Inc. (2002). Aranesp (darbepoetin alfa) [Prescribing information]. Thousand Oaks, CA: Author.

Amorajabi, M., Tchekmedyian, S., & Kallich, J. (2003, May). Patient-reported depression and anxiety in patients with cancer improves following reduction in anemia-related fatigue with darbepoetin alfa therapy [Abstract 118]. Poster presented at the 28th Annual Congress of the Oncology Nursing Society, Denver, CO.

Berndt, E., Kallich, J., Xu, X., Erder, M.H., Lee, H., & Glaspy, J. (2002). Reductions in anemia and fatigue are associated with improvements in productivity [Abstract 3454]. Blood, 100, 876a.

Beveridge, R.A., Rifkin, R.M., Moleski, R.J., Milkovich, G., Reitan, J.F., Paivanas, T.A., et al. (2003). Impact of long-acting growth factors on practice dynamics and patient satisfaction. Pharmacotherapy, 23(12, Pt. 2), 101S-109S.

Boccia, R., Davidson, S., Tomita, D., Green, L., & Smith, R.E. (2003). Usage and clinical outcomes of erythropoietic proteins for the treatment of chemotherapy-induced anemia (CIA): Clinical Evaluation of Anemia Response (CLEAR), a multicenter, retrospective cohort study [Abstract 2761]. Blood, 102, 748a.

Bootman, J.L., Townsend, R.J., & McGhan, W.F. (Eds.). (1996). Principles of pharmacoeconomics. Cincinnati, OH: H. Whitney Books.

Buchsel, P.C., Murphy, B.J., & Newton, S.A. (2002). Epoetin alfa: Current and future indications and nursing implications. Clinical Journal of Oncology Nursing, 6, 261-267.

Byar, K., & Berger, A. (2003, May). Women receiving adjuvant chemotherapy for breast cancer: Impact on quality of life and fatigue [Abstract 142]. Poster presented at the 28th Annual Congress of the Oncology Nursing Society, Denver, CO.

Cella, D. (1998). Factors influencing quality of life in cancer patients: Anemia and fatigue. Seminars in Oncology, 25(3, Suppl. 7), 43-46.

Cella, D. (2002). The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology, 16(9, Suppl. 10), 125-132.

Cella, D., Eton, D.T., Lai, J.S., Peterman, A.H., & Merkel, D.E. (2002). Combining anchor and distribution-based methods to derive minimal clinically meaningful differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24, 547-561.

Cella, D., Lai, J.S., Chang, C.H., Peterman, A., & Slavin, M. (2002). Fatigue in cancer patients compared with fatigue in the general United States population. Cancer, 94, 528-538.

Cleeland, C.S., Gabrilove, J., Crawford, J., Mendes, E., Lubeck, D., Tomita, D., et al. (2003). Assessing symptom burden using the M.D. Anderson Symptom Inventory (MDASI) in patients with chemotherapy-induced anemia: Early results of a multicenter, open-label study of patients treated with darbepoetin alfa 200 mcg every two weeks [Abstract 2765]. Blood, 102, 749a.

Cleeland, C.S., Mendoza, T.R., Wang, X.S., Chou, C., Harle, M.T., Morrissey, M., et al. (2000). Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer, 89, 1634-1646.

Crawford, J., Demetri, G.D., Gabrilove, J.L., Blasi, M.V., Sarokhan, B.J., & Glaspy, J. (2002). Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clinical Lung Cancer, 3, 180-190.

Curt, G. A. (2000). Impact of fatigue on quality of life in oncology patients. Seminars in Hematology, 37(4, Suppl. 6), 14-17.

Demetri, G.D., Kris, M., Wade, J., Degos, L., & Cella, D. (1998). Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Journal of Clinical Oncology, 16, 3412-3425.

Egrie, J.C., Dwyer, E., Browne, J.K., Hitz, A., & Lykos, M.A. (2003). Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Experimental Hematology, 31, 290-299.

Erslev, A.J. (2000). Erythropoietin and anemia of cancer. European Journal of Haematology, 64, 353-358.

Gabrilove, J., Crawford, J., Swan, F., Mendes, E., Tomita, D., Colowick, A., et al. (2003). A multicenter study to assess the effects of darbepoetin alfa 200 mcg every two weeks (Q2W) in patients with nonmyeloid malignancies receiving chemotherapy: Early results of the SURPASS study [Abstract 3778]. Blood, 102, 19b.

Gabrilove, J.L., Cleeland, C.S., Livingston, R.B., Sarokhan, B., Winer, E., & Einhorn, L.H. (2001). Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19, 2875-2882.

Gillespie, T.W. (2002). Effects of cancer-related anemia on clinical and quality of life outcomes. Clinical Journal of Oncology Nursing, 6, 206-211.

Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S. (1997). Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Journal of Clinical Oncology, 15, 1218-1234.

Glaspy, J.A., Jadeja, J.S., Justice, G., Kessler, J., Richards, D., Schwartzberg, L., et al. (2002). Darbepoetin alfa given every one or two weeks alleviates anaemia associated with cancer chemotherapy. British Journal of Cancer, 87, 268-276.

Glaspy, J.A., & Tchekmedyian, N.S. (2002). Darbepoetin alfa administered every two weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology, 16(10, Suppl. 11), 23-29.

Groopman, J.E., & Itri, L.M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.

Haithcox, S., Ramnes, C., Lee, H., Lu, J., & Lyman, G.H. (2003). The impact of frequent injections for hematopoietic growth factor support in patients receiving chemotherapy: An observational study. BMC Nursing, 2(1), 2.

Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schipperus, M.R., Juvonen, E., et al. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394-403.

Henke, M., Laszig, R., Rube, C., Schafer, U., Haase, K.D., Schilcher, B., et al. (2003). Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet, 362, 1255-1260.

Holzner, B., Kemmler, G., Greil, R., Kopp, M., Zeimet, A., Raderer, M., et al. (2002). The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Annals of Oncology, 13, 965-973.

Johnston, E., & Crawford, J. (1998). The hematologic support of the cancer patient. In A. Berger, R.K. Portenoy, & D.E. Weissman (Eds.), Principles and practices of supportive oncology (pp. 549-569). Philadelphia: Lippincott-Raven.

Jumbe, N., Yao, B., Rovetti, R., Rossi, G., & Heatherington, A. (2002). Clinical trial simulation of a 200-mcg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology, 16(10, Suppl. 11), 37-44.

Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A.B., et al. (2003). Darbepoetin alfa administered every three weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: Results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer, 39, 2026-2034.

Kunikane, H., Watanabe, K., Fukuoka, M., Saijo, N., Furuse, K., Ikegami, H., et al. (2001). Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. International Journal of Clinical Oncology, 6, 296-301.

Lawless, G., Wilson-Royalty, M., & Meyers, J. (2000). Epoetin alfa practice pattern usage in community practice sites [Abstract 5446]. Blood, 96, 390b.

Lee, S.J., Liljas, B., Churchill, W.H., Popovsky, M.A., Stowell, C.P., Cannon, M.E., et al. (1998). Perceptions and preferences of autologous blood donors. Transfusion, 38, 757-763.

Leyland-Jones, B. (2003). Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology, 4, 459-460.

Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E., & Rapoport, B. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865-2874.

Ludwig, H., Birgegard, G., Barrett-Lee, P.J., & Krzakowski, M. (2002). Prevalence and management of anemia in patients (pts) with hematologic malignancies (HMs) and solid tumors (STs): Results from the European Cancer Anaemia Survey (ECAS) [Abstract 884]. Blood, 100, 234a.

Ludwig, H., & Pecorelli, S. (2000). Suboptimal hemoglobin levels: Do they impact patients and their therapy? Audience responses. Seminars in Oncology, 27(2, Suppl. 4), 18-19.

Meehan, K.R., Tchekmedyian, S., Smith, R.E., Jr., Kleinman, L., Fitzmaurice, T., & Kallich, J.D. (2002). An activity based costing estimate of anemia correction activities in an oncology practice [Abstract 5595]. Blood, 100, 502b.

Mercadante, S., Gebbia, V., Marrazzo, A., & Filosto, S. (2000). Anaemia in cancer: Pathophysiology and treatment. Cancer Treatment Reviews, 26, 303-311.

Miller, C.B., Jones, R.J., Piantadosi, S., Abeloff, M.D., & Spivak, J.L. (1990). Decreased erythropoietin response in patients with the anemia of cancer. New England Journal of Medicine, 322, 1689-1692.

Mirtsching, B.C., Beck, J.T., Charu, V., Nazha, N.T., Tchekmedyian, N.S., Ghazal, H., et al. (2003). Darbepoetin alfa administered every two weeks (Q2W) reduces chemotherapy-induced anemia (CIA) to the same extent as recombinant human erythropoietin (rHuEPO) but with less-frequent dosing [Abstract 2944]. Proceedings of the American Society of Clinical Oncology, 22, 732.

Mock, V., & Olsen, M. (2003). Current management of fatigue and anemia in patients with cancer. Seminars in Oncology Nursing, 19(4, Suppl. 2), 36-41.

Montserrat, E., Bosch, F., & Rozman, C. (1997). B-cell chronic lymphocytic leukemia: Recent progress in biology, diagnosis, and therapy. Annals of Oncology, 8(Suppl. 1), 93-101.

Moore, K. (2002, July). Impact of medical visits on the patient and caregiver: Every day counts. Point of Care Perspectives, 1-4.

Moore, K., Fortner, B., & Okon, T. (2003, May). The impact of medical visits on patients with cancer [Abstract 73]. Poster presented at the 28th Annual Congress of the Oncology Nursing Society, Denver, CO.

Nail, L.M. (2002). Fatigue in patients with cancer. Oncology Nursing Forum, 29, 537-544.

Ortho Biotech Products, L.P. (2000). Procrit (epoetin alfa) [Prescribing information]. Bridgewater, NJ: Author.

Osterborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., et al. (2002). Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. Journal of Clinical Oncology, 20, 2486-2494.

Patton, J., Reeves, T., & Wallace, J.F. (2003, May). Darbepoetin alfa 200 mcg every two weeks (Q2W) and epoetin alfa 40,000 U every week (QW) in chemotherapy-induced anemia patients result in similar initial hemoglobin outcomes. Presented at the International Society for Pharmacoeconomics and Outcomes Research 8th Annual International Meeting, Arlington, VA.

Quirt, I., Robeson, C., Lau, C.Y., Kovacs, M., Burdette-Radoux, S., Dolan, S., et al. (2001). Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. Journal of Clinical Oncology, 19, 4126-4134.

Red Book™. (2003, December). Thomson Micromedex. Greenwood Village, CO: Author.

Reeves, T.J., Wallace, J.F., & Patton, J.F. (2003, December). Darbepoetin alfa is comparable to epoetin alfa for chemotherapy induced anemia in clinical practice [Abstract P-500]. Presented at the 38th American Society of Health-System Pharmacists Annual Midyear Clinical Meeting, New Orleans, LA.

Rizzo, J.D., Lichtin, A.E., Woolf, S.H., Seidenfeld, J., Bennett, C.L., Cella, D., et al. (2002). Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood, 100, 2303-2320.

Schwartzberg, L., Shiffman, R., Tomita, D., Stolshek, B., Rossi, G., & Adamson, R. (2003). A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clinical Therapeutics, 25, 2781-2796.

Schwartzberg, L.S., Yee, L.K., Senecal, F.M., Charu, V., Tomita, D., Wallace, J., et al. (2004). A randomized comparison of every-two-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung or gynecologic cancer. Oncologist, 9, 696-707.

Singer, M., & Patel, A. (2002, April). Improving symptom management in an ambulatory oncology clinic [Abstract 32]. Podium session presented at the 27th Annual Congress of the Oncology Nursing Society, Washington, DC.

Tchekmedyian, N.S. (2001). New frontiers in oncology supportive care: Anemia management. Primary Care and Cancer, 21, 9-12.

Tchekmedyian, N.S. (2002). Anemia in cancer patients: Significance, epidemiology, and current therapy. Oncology, 16(9, Suppl. 10), 17-24.

Tchekmedyian, N.S., Kallich, J., McDermott, A., Fayers, P., & Erder, M.H. (2003). The relationship between psychologic distress and cancer-related fatigue. Cancer, 98, 198-203.

Thames, W., Yao, B., Scheifele, A., & Alley, J.L. (2003). Drug use evaluation (DUE) of darbepoetin alfa in anemic patients undergoing chemotherapy supports a fixed dose of 200 mcg Q2W given every two weeks (Q2W) [Abstract 2196]. Proceedings of the American Society of Clinical Oncology, 22, 546.

Vadhan-Raj, S., Mirtsching, B., Charu, V., Terry, D., Rossi, G., Tomita, D., et al. (2003). Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks. Journal of Supportive Oncology, 1, 131-138.

Vansteenkiste, J., Pirker, R., Massuti, B., Barata, F., Font, A., Fiegl, M., et al. (2002). Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. Journal of the National Cancer Institute, 94, 1211-1220.

Vansteenkiste, J., Tomita, D., Rossi, G., & Pirker, R. (2004). Darbepoetin alfa in lung cancer patients on chemotherapy: A retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Supportive Care in Cancer, 12, 253-262.

Wun, T., Law, L., Harvey, D., Sieracki, B., Scudder, S.A., & Ryu, J.K. (2003). Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer, 98, 1514-1520.

Yellen, S.B., Cella, D.F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13, 63-74.